Sökning: "Cost of Illness"
Visar resultat 6 - 10 av 44 avhandlingar innehållade orden Cost of Illness.
6. The burden of stroke in Sweden studies on costs and quality of life based on Riks-Stroke, the Swedish stroke registerDetta är en avhandling från Umeå : Umeå university
Sammanfattning : The costs for stroke management and reduced health related quality of life (QoL) can extend throughout life as mental and physical disabilities are common. The aim of this thesis was to quantify this stroke-related burden with data from Riks-Stroke (RS), the Swedish stroke register. LÄS MER
- Detta är en avhandling från Stockholm : Karolinska Institutet, Department of Learning, Informatics, Management and Ethics (Lime)
Sammanfattning : Breast cancer is a major cause of morbidity and mortality. Resources are spent in order to prevent, diagnose, and treat breast cancer. Since health care resources are limited, these resources must be allocated in an optimal way in order to maximise health. LÄS MER
- Detta är en avhandling från Stockholm : Karolinska Institutet, Department of Neurobiology, Care Sciences and Society
Sammanfattning : Aim: The overall aim of this thesis was to provide a comprehensive description of how individuals may be affected by GuillainBarré syndrome (GBS), in terms of on body function, activity, and participation as well as on healthrelated quality of fife, and describe changes over time during the first 2 years after onset. Other aims were to describe the use of healthcare and patient satisfaction, and to report on the subjective experiences of failing ill with GBS. LÄS MER
- Detta är en avhandling från Umeå : Umeå University
Sammanfattning : Background InVietnam, the proportion of people aged 60 and above has increased rapidly in recent decades. The majority live in rural areas where socioeconomic status is more disadvantaged than in urban areas.Vietnam’s economic status is improving but disparities in income and living conditions are widening between groups and regions. LÄS MER
- Detta är en avhandling från Stockholm : Karolinska Institutet, Institute of Environmental Medicine
Sammanfattning : Duchenne muscular dystrophy (DMD) is a rare neuromuscular disease characterized by progressive muscle degeneration resulting in loss of independent ambulation, serious multisystem complications, and a mean life expectancy at birth of about 25 years. Several therapies are on the horizon for DMD and it has thus become urgent to better understand the health economic context of the disease to enable assessments of cost-effectiveness and inform decisions regarding reimbursement of new health technologies. LÄS MER